Anavex Life Sciences Corp (AVXL) Financiero

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.